EA202191001A1 - COMPOUNDS FOR TREATMENT OF ARENAVIRAL INFECTION - Google Patents

COMPOUNDS FOR TREATMENT OF ARENAVIRAL INFECTION

Info

Publication number
EA202191001A1
EA202191001A1 EA202191001A EA202191001A EA202191001A1 EA 202191001 A1 EA202191001 A1 EA 202191001A1 EA 202191001 A EA202191001 A EA 202191001A EA 202191001 A EA202191001 A EA 202191001A EA 202191001 A1 EA202191001 A1 EA 202191001A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
compounds
arenaviral
infection
arenavirus
Prior art date
Application number
EA202191001A
Other languages
Russian (ru)
Inventor
Эрик Браун
Видиасагар Редди Гантла
Надежда Соколова
Майкл Бруно Плю
Грэгори Хенкел
Кеннет Маккормак
Original Assignee
Арисен Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арисен Терапьютикс, Инк. filed Critical Арисен Терапьютикс, Инк.
Publication of EA202191001A1 publication Critical patent/EA202191001A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Соединения, примером которых является соединение А, пригодны для лечения аренавирусных инфекций и вирусных инфекций, опосредованных гликопротеинами аренавируса.Compounds exemplified by Compound A are useful in the treatment of arenavirus infections and viral infections mediated by arenavirus glycoproteins.

EA202191001A 2018-12-06 2019-12-03 COMPOUNDS FOR TREATMENT OF ARENAVIRAL INFECTION EA202191001A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776390P 2018-12-06 2018-12-06
PCT/US2019/064223 WO2020117794A1 (en) 2018-12-06 2019-12-03 Compounds for the treatment of arenavirus infection

Publications (1)

Publication Number Publication Date
EA202191001A1 true EA202191001A1 (en) 2021-08-16

Family

ID=70975517

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191001A EA202191001A1 (en) 2018-12-06 2019-12-03 COMPOUNDS FOR TREATMENT OF ARENAVIRAL INFECTION

Country Status (11)

Country Link
EP (1) EP3890731A4 (en)
JP (1) JP2022509763A (en)
KR (1) KR20210106997A (en)
CN (1) CN113329750A (en)
AR (1) AR117228A1 (en)
AU (1) AU2019393784A1 (en)
BR (1) BR112021010909A2 (en)
CA (1) CA3118765A1 (en)
EA (1) EA202191001A1 (en)
MX (1) MX2021005234A (en)
WO (1) WO2020117794A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293638T3 (en) * 1994-03-25 2008-03-16 Isotechnika, Inc. IMPROVEMENT OF THE EFFECTIVENESS OF PHARMACOS BY DEUTERATION.
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN104507473A (en) * 2012-02-17 2015-04-08 奇尼塔四有限责任公司 Antiviral drugs for treatment of arenavirus infection
WO2018013430A2 (en) * 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection

Also Published As

Publication number Publication date
WO2020117794A1 (en) 2020-06-11
BR112021010909A2 (en) 2021-08-24
KR20210106997A (en) 2021-08-31
AR117228A1 (en) 2021-07-21
CA3118765A1 (en) 2020-06-11
JP2022509763A (en) 2022-01-24
EP3890731A4 (en) 2022-08-17
AU2019393784A1 (en) 2021-05-27
MX2021005234A (en) 2021-08-11
EP3890731A1 (en) 2021-10-13
CN113329750A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
EA201890735A1 (en) Modulators of the cow protein of the hepatitis B virus
PH12019500335A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
DOP2019000225A (en) CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USE OF THEM
EA201592126A1 (en) 6-BRIDGED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
EA201791886A1 (en) ANTI-VIRUS CONNECTIONS
EA201791515A1 (en) COMPOUNDS OF PYRAZINE FOR THE TREATMENT OF INFECTIOUS DISEASES
MX2023013140A (en) Vaccines against hepatitis b virus.
EA201790630A1 (en) METHODS OF OBTAINING RIBOSIDS
MD3582853T2 (en) Cyclic di-nucleotides compounds for the treatment of cancer
EA201691726A1 (en) NEW 6-CONDENSED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION
EA201792069A1 (en) DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B
EA201691261A1 (en) NEW DIHYDROCHINOLYSINES FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY THE HEPATITIS B VIRUS
EA201692358A1 (en) IZOINDOLIN DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTION
EA201792021A1 (en) JAK INHIBITOR
EA202190854A1 (en) HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS
EA201891666A1 (en) ARYL SUBSTITUTE PYRIMIDINES FOR APPLICATION IN INFECTION CAUSED BY THE VIRUS VIRUS
EA201591362A1 (en) COMPOUNDS AND METHODS OF TREATING BACTERIAL INFECTIONS
BR112017026061A2 (en) compound, use of a compound, and method of treating a viral infection
EA202092171A1 (en) DOSING SCHEME OF THE MODULATOR ASSEMBLY OF CAPSIDE
EA201992233A1 (en) COMPOUNDS OF ISOXOXOLICARBOXAMIDE AND THEIR APPLICATION
EA202190046A1 (en) N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND THEIR APPLICATION
EA201892375A1 (en) METHODS FOR TREATING INFECTIONS CAUSED BY HEPATITIS B VIRUS
EA202191192A1 (en) CRYSTALLINE SALTS OF PLASMA CALLICREIN INHIBITOR
EA202090693A1 (en) NEW MEK INHIBITOR FOR TREATMENT OF VIRAL AND BACTERIAL INFECTIONS
EA202191001A1 (en) COMPOUNDS FOR TREATMENT OF ARENAVIRAL INFECTION